1.
Rev. méd. Chile
; 143(7): 895-904, jul. 2015. tab
Artículo
en Español
| LILACS
| ID: lil-757915
RESUMEN
Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.